This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dvorak, H. F. Search for Related Content PubMed PubMed Citation Articles by Dvorak, H. F. Social Bookmarking                            What's this?

Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy

From the Department of Pathology, Beth Israel Deaconess Medical Center, and Department of Pathology, Harvard Medical School, Boston, MA.

Address reprint requests to Harold F. Dvorak, MD, Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215; email: hdvorak{at}caregroup.harvard.edu

ABSTRACT: Vascular endothelial growth factor A (VEGF-A), the founding member of the vascular permeability factor (VPF)/VEGF family of proteins, is an important angiogenic cytokine with critical roles in tumor angiogenesis. This article reviews the literature with regard to VEGF-A’s multiple functions, the mechanisms by which it induces angiogenesis, and its current and projected roles in clinical oncology. VEGF-A is a multifunctional cytokine that is widely expressed by tumor cells and that acts through receptors (VEGFR-1, VEGFR-2, and neuropilin) that are expressed on vascular endothelium and on some other cells. It increases microvascular permeability, induces endothelial cell migration and division, reprograms gene expression, promotes endothelial cell survival, prevents senescence, and induces angiogenesis. Recently, VEGF-A has also been shown to induce lymphangiogenesis. Measurements of circulating levels of VEGF-A may have value in estimating prognosis, and VEGF-A and its receptors are potential targets for therapy. Recognized as the single most important angiogenic cytokine, VEGF-A has a central role in tumor biology and will likely have an important role in future approaches designed to evaluate patient prognosis. It may also become an important target for cancer therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Li, M. Kuchimanchi, D. Hickman, L. Poppe, M. Hayashi, Y. Zhou, R. Subramanian, G. Kumar, and S. Surapaneni In Vitro Metabolism of the Novel, Highly Selective Oral Angiogenesis Inhibitor Motesanib Diphosphate in Preclinical Species and in Humans Drug Metab. Dispos., July 1, 2009; 37(7): 1378 - 1394. [Abstract] [Full Text] [PDF]

				A. G. Sorensen, T. T. Batchelor, W.-T. Zhang, P.-J. Chen, P. Yeo, M. Wang, D. Jennings, P. Y. Wen, J. Lahdenranta, M. Ancukiewicz, et al. A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients Cancer Res., July 1, 2009; 69(13): 5296 - 5300. [Abstract] [Full Text] [PDF]

				B. I. Rini Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient J. Clin. Oncol., July 1, 2009; 27(19): 3225 - 3234. [Abstract] [Full Text] [PDF]

				D. R. Soto-Pantoja, J. Menon, P. E. Gallagher, and E. A. Tallant Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor Mol. Cancer Ther., June 1, 2009; 8(6): 1676 - 1683. [Abstract] [Full Text] [PDF]

				W. S. Kamoun, C. D. Ley, C. T. Farrar, A. M. Duyverman, J. Lahdenranta, D. A. Lacorre, T. T. Batchelor, E. di Tomaso, D. G. Duda, L. L. Munn, et al. Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice J. Clin. Oncol., May 20, 2009; 27(15): 2542 - 2552. [Abstract] [Full Text] [PDF]

				E. O. Hanrahan, A. J. Ryan, H. Mann, S. J. Kennedy, P. Langmuir, R. B. Natale, R. S. Herbst, B. E. Johnson, and J. V. Heymach Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3600 - 3609. [Abstract] [Full Text] [PDF]

				M. Rodewald, D. Herr, W.C. Duncan, H.M. Fraser, G. Hack, R. Konrad, F. Gagsteiger, R. Kreienberg, and C. Wulff Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability Hum. Reprod., May 1, 2009; 24(5): 1191 - 1199. [Abstract] [Full Text] [PDF]

				B. Ren, K. Song, S. Parangi, T. Jin, M. Ye, R. Humphreys, M. Duquette, X. Zhang, N. Benhaga, J. Lawler, et al. A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR Cancer Res., May 1, 2009; 69(9): 3856 - 3865. [Abstract] [Full Text] [PDF]

				T.-W. Chung, S.-J. Kim, H.-J. Choi, K.-J. Kim, M.-J. Kim, S.-H. Kim, H.-J. Lee, J.-H. Ko, Y.-C. Lee, A. Suzuki, et al. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2 Glycobiology, March 1, 2009; 19(3): 229 - 239. [Abstract] [Full Text] [PDF]

				E. Kurtagic, M. P. Jedrychowski, and M. A. Nugent Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L534 - L546. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]

				B. I. Rini, S. Halabi, J. E. Rosenberg, W. M. Stadler, D. A. Vaena, S.-S. Ou, L. Archer, J. N. Atkins, J. Picus, P. Czaykowski, et al. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 J. Clin. Oncol., November 20, 2008; 26(33): 5422 - 5428. [Abstract] [Full Text] [PDF]

				A. M. Schultheis, G. Lurje, K. E. Rhodes, W. Zhang, D. Yang, A. A. Garcia, R. Morgan, D. Gandara, S. Scudder, A. Oza, et al. Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab Clin. Cancer Res., November 15, 2008; 14(22): 7554 - 7563. [Abstract] [Full Text] [PDF]

				Y. Wu, Y.-Y. Li, K. Matsushima, T. Baba, and N. Mukaida CCL3-CCR5 Axis Regulates Intratumoral Accumulation of Leukocytes and Fibroblasts and Promotes Angiogenesis in Murine Lung Metastasis Process J. Immunol., November 1, 2008; 181(9): 6384 - 6393. [Abstract] [Full Text] [PDF]

				L. M. Ellis and D. J. Hicklin Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy Clin. Cancer Res., October 15, 2008; 14(20): 6371 - 6375. [Abstract] [Full Text] [PDF]

				C Lopez-Pedrera, N Barbarroja, M. Aguirre, L. Torres, F Velasco, and M. Cuadrado Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases Lupus, October 1, 2008; 17(10): 905 - 916. [Abstract] [PDF]

				G. Lurje, W. Zhang, A. M. Schultheis, D. Yang, S. Groshen, A. E. Hendifar, H. Husain, M. A. Gordon, F. Nagashima, H. M. Chang, et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer Ann. Onc., October 1, 2008; 19(10): 1734 - 1741. [Abstract] [Full Text] [PDF]

				O. Fainaru, I. Adini, O. Benny, L. Bazinet, E. Pravda, R. D'Amato, and J. Folkman Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability FASEB J, October 1, 2008; 22(10): 3728 - 3735. [Abstract] [Full Text] [PDF]

				H. M. Fraser, H. Wilson, A. Silvestri, K. D. Morris, and S. J. Wiegand The Role of Vascular Endothelial Growth Factor and Estradiol in the Regulation of Endometrial Angiogenesis and Cell Proliferation in the Marmoset Endocrinology, September 1, 2008; 149(9): 4413 - 4420. [Abstract] [Full Text] [PDF]

				E. I. Ager, J. Neo, and C. Christophi The renin-angiotensin system and malignancy Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684. [Abstract] [Full Text] [PDF]

				C. L. Estilo, M. Fornier, A. Farooki, D. Carlson, G. Bohle III, and J. M. Huryn Osteonecrosis of the Jaw Related to Bevacizumab J. Clin. Oncol., August 20, 2008; 26(24): 4037 - 4038. [Full Text] [PDF]

				S. K. Chang, I. Rizvi, N. Solban, and T. Hasan In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153. [Abstract] [Full Text] [PDF]

				C. Sarkar, D. Chakroborty, U. R. Chowdhury, P. S. Dasgupta, and S. Basu Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models Clin. Cancer Res., April 15, 2008; 14(8): 2502 - 2510. [Abstract] [Full Text] [PDF]

				N. T. Fernando, M. Koch, C. Rothrock, L. K. Gollogly, P. A. D'Amore, S. Ryeom, and S. S. Yoon Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors Clin. Cancer Res., March 1, 2008; 14(5): 1529 - 1539. [Abstract] [Full Text] [PDF]

				K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, E. A. Perez, T. Shenkier, D. Cella, and N. E. Davidson Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer N. Engl. J. Med., December 27, 2007; 357(26): 2666 - 2676. [Abstract] [Full Text] [PDF]

				L. Krishnan, J. B. Hoying, H. Nguyen, H. Song, and J. A. Weiss Interaction of angiogenic microvessels with the extracellular matrix Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3650 - H3658. [Abstract] [Full Text] [PDF]

				M. L. Petreaca, M. Yao, Y. Liu, K. DeFea, and M. Martins-Green Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) Is Required for IL-8/CXCL8-induced Endothelial Permeability Mol. Biol. Cell, December 1, 2007; 18(12): 5014 - 5023. [Abstract] [Full Text] [PDF]

				R. A. Burger, M. W. Sill, B. J. Monk, B. E. Greer, and J. I. Sorosky Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., November 20, 2007; 25(33): 5165 - 5171. [Abstract] [Full Text] [PDF]

				A. Grothey Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate? Clin. Cancer Res., November 15, 2007; 13(22): 6909s - 6912s. [Abstract] [Full Text] [PDF]

				T. Kaneko, Z. Zhang, M. G. Mantellini, E. Karl, B. Zeitlin, M. Verhaegen, M. S. Soengas, M. Lingen, R. M. Strieter, G. Nunez, et al. Bcl-2 Orchestrates a Cross-talk between Endothelial and Tumor Cells that Promotes Tumor Growth Cancer Res., October 15, 2007; 67(20): 9685 - 9693. [Abstract] [Full Text] [PDF]

				O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]

				B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N. P. Ziats, J. K. Wasman, et al. Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin Clin. Cancer Res., October 1, 2007; 13(19): 5862 - 5868. [Abstract] [Full Text] [PDF]

				T. Cindrova-Davies, H.-W. Yung, J. Johns, O. Spasic-Boskovic, S. Korolchuk, E. Jauniaux, G. J. Burton, and D. S. Charnock-Jones Oxidative Stress, Gene Expression, and Protein Changes Induced in the Human Placenta during Labor Am. J. Pathol., October 1, 2007; 171(4): 1168 - 1179. [Abstract] [Full Text] [PDF]

				H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5544s - 5548s. [Abstract] [Full Text] [PDF]

				D. G. Duda, R. K. Jain, and C. G. Willett Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers J. Clin. Oncol., September 10, 2007; 25(26): 4033 - 4042. [Abstract] [Full Text] [PDF]

				L. Xu and R. K. Jain Down-Regulation of Placenta Growth Factor by Promoter Hypermethylation in Human Lung and Colon Carcinoma Mol. Cancer Res., September 1, 2007; 5(9): 873 - 880. [Abstract] [Full Text] [PDF]

				R. A. Burger Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2902 - 2908. [Abstract] [Full Text] [PDF]

				R. Kumar, V. B. Knick, S. K. Rudolph, J. H. Johnson, R. M. Crosby, M.-C. Crouthamel, T. M. Hopper, C. G. Miller, L. E. Harrington, J. A. Onori, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol. Cancer Ther., July 1, 2007; 6(7): 2012 - 2021. [Abstract] [Full Text] [PDF]

				L. S. Rosen, R. Kurzrock, M. Mulay, A. Van Vugt, M. Purdom, C. Ng, J. Silverman, A. Koutsoukos, Y.-N. Sun, M. B. Bass, et al. Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors J. Clin. Oncol., June 10, 2007; 25(17): 2369 - 2376. [Abstract] [Full Text] [PDF]

				M. W. Saif, A. Elfiky, and R. R. Salem Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer Ann. Surg. Oncol., June 1, 2007; 14(6): 1860 - 1869. [Abstract] [Full Text] [PDF]

				J. A. Garcia and B. I. Rini Recent Progress in the Management of Advanced Renal Cell Carcinoma CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125. [Abstract] [Full Text] [PDF]

				N. Steeghs, J. W. R. Nortier, and H. Gelderblom Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments Ann. Surg. Oncol., February 1, 2007; 14(2): 942 - 953. [Abstract] [Full Text] [PDF]

				T. Groten, H.M. Fraser, W.C. Duncan, R. Konrad, R. Kreienberg, and C. Wulff Cell junctional proteins in the human corpus luteum: changes during the normal cycle and after HCG treatment Hum. Reprod., December 1, 2006; 21(12): 3096 - 3102. [Abstract] [Full Text] [PDF]

				C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al. Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer. J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570. [Abstract] [Full Text] [PDF]

				K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res., September 15, 2006; 66(18): 9134 - 9142. [Abstract] [Full Text] [PDF]

				K. Shchors, E. Shchors, F. Rostker, E. R. Lawlor, L. Brown-Swigart, and G. I. Evan The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta Genes & Dev., September 15, 2006; 20(18): 2527 - 2538. [Abstract] [Full Text] [PDF]

				M. Basche, D. L. Gustafson, S. N. Holden, C. L. O'Bryant, L. Gore, S. Witta, M. K. Schultz, M. Morrow, A. Levin, B. R. Creese, et al. A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors. Clin. Cancer Res., September 15, 2006; 12(18): 5471 - 5480. [Abstract] [Full Text] [PDF]

				L. Y. Han, C. N. Landen, J. G. Trevino, J. Halder, Y. G. Lin, A. A. Kamat, T.-J. Kim, W. M. Merritt, R. L. Coleman, D. M. Gershenson, et al. Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Res., September 1, 2006; 66(17): 8633 - 8639. [Abstract] [Full Text] [PDF]

				A. Polverino, A. Coxon, C. Starnes, Z. Diaz, T. DeMelfi, L. Wang, J. Bready, J. Estrada, R. Cattley, S. Kaufman, et al. AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts. Cancer Res., September 1, 2006; 66(17): 8715 - 8721. [Abstract] [Full Text] [PDF]

				B. Giantonio, D. Levy, P. O'Dwyer, N. Meropol, P. Catalano, and A. Benson III A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200 Ann. Onc., September 1, 2006; 17(9): 1399 - 1403. [Abstract] [Full Text] [PDF]

				D. You, L. Waeckel, T. G. Ebrahimian, O. Blanc-Brude, P. Foubert, V. Barateau, M. Duriez, S. LeRicousse-Roussanne, J. Vilar, E. Dejana, et al. Increase in Vascular Permeability and Vasodilation Are Critical for Proangiogenic Effects of Stem Cell Therapy Circulation, July 25, 2006; 114(4): 328 - 338. [Abstract] [Full Text] [PDF]

				A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions Oncologist, July 1, 2006; 11(7): 753 - 764. [Abstract] [Full Text] [PDF]

				J. Cai, C. Parr, G. Watkins, W. G. Jiang, and M. Boulton Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin. Cancer Res., June 1, 2006; 12(11): 3510 - 3517. [Abstract] [Full Text] [PDF]

				M. D. Groves, J. C. Reijneveld, and D. Brandsma CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases Neurology, May 23, 2006; 66(10): 1609 - 1610. [Full Text] [PDF]

				L. M. Ellis The role of neuropilins in cancer Mol. Cancer Ther., May 1, 2006; 5(5): 1099 - 1107. [Abstract] [Full Text] [PDF]

				K. Nakano, Y. Adachi, K. Minamino, M. Iwasaki, A. Shigematsu, N. Kiriyama, Y. Suzuki, Y. Koike, H. Mukaide, S. Taniuchi, et al. Mechanisms Underlying Acceleration of Blood Flow Recovery in Ischemic Limbs by Macrophage Colony-Stimulating Factor Stem Cells, May 1, 2006; 24(5): 1274 - 1279. [Abstract] [Full Text] [PDF]

				E. R. Camp, A. Yang, W. Liu, F. Fan, R. Somcio, D. J. Hicklin, and L. M. Ellis Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2628 - 2633. [Abstract] [Full Text] [PDF]

				E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]

				M. Hossein Pourgholami, Z. Yan Cai, Y. Lu, L. Wang, and D. Lawson Morris Albendazole: a Potent Inhibitor of Vascular Endothelial Growth Factor and Malignant Ascites Formation in OVCAR-3 Tumor-Bearing Nude Mice. Clin. Cancer Res., March 15, 2006; 12(6): 1928 - 1935. [Abstract] [Full Text] [PDF]

				C. H. Crane, L. M. Ellis, J. L. Abbruzzese, C. Amos, H. Q. Xiong, L. Ho, D. B. Evans, E. P. Tamm, C. Ng, P. W.T. Pisters, et al. Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1145 - 1151. [Abstract] [Full Text] [PDF]

				S. S. Yoon, S. H. Kim, M. Gonen, N. M. Heffernan, K. Y. Detwiller, W. R. Jarnagin, M. D'Angelica, L. H. Blumgart, K. K. Tanabe, and R. P. DeMatteo Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases Ann. Surg. Oncol., March 1, 2006; 13(3): 353 - 362. [Abstract] [Full Text] [PDF]

				A. P. Hall, F. R. Westwood, and P. F. Wadsworth Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate Toxicol Pathol, February 1, 2006; 34(2): 131 - 147. [Abstract] [Full Text] [PDF]

				D. Mehta and A. B. Malik Signaling Mechanisms Regulating Endothelial Permeability Physiol Rev, January 1, 2006; 86(1): 279 - 367. [Abstract] [Full Text] [PDF]

				S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798. [Abstract] [Full Text] [PDF]

				P. Religa, R. Cao, M. Bjorndahl, Z. Zhou, Z. Zhu, and Y. Cao Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels Blood, December 15, 2005; 106(13): 4184 - 4190. [Abstract] [Full Text] [PDF]

				S. Faderl, K.-A. Do, M. M. Johnson, M. Keating, S. O'Brien, I. Jilani, A. Ferrajoli, F. Ravandi-Kashani, C. Aguilar, A. Dey, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia Blood, December 15, 2005; 106(13): 4303 - 4307. [Abstract] [Full Text] [PDF]

				H. Yamashita, J. Kitayama, and H. Nagawa Hyperfibrinogenemia is a Useful Predictor for Lymphatic Metastasis in Human Gastric Cancer Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 595 - 600. [Abstract] [Full Text] [PDF]

				Z. Kan, S. Phongkitkarun, S. Kobayashi, Y. Tang, L. M. Ellis, T. Y. Lee, and C. Charnsangavej Functional CT for Quantifying Tumor Perfusion in Antiangiogenic Therapy in a Rat Model Radiology, October 1, 2005; 237(1): 151 - 158. [Abstract] [Full Text] [PDF]

				R. Hallmann, N. Horn, M. Selg, O. Wendler, F. Pausch, and L. M. Sorokin Expression and Function of Laminins in the Embryonic and Mature Vasculature Physiol Rev, July 1, 2005; 85(3): 979 - 1000. [Abstract] [Full Text] [PDF]

				K. Y. Detwiller, N. T. Fernando, N. H. Segal, S. W. Ryeom, P. A. D'Amore, and S. S. Yoon Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor A Cancer Res., July 1, 2005; 65(13): 5881 - 5889. [Abstract] [Full Text] [PDF]

				J. V. Alvarez, P. G. Febbo, S. Ramaswamy, M. Loda, A. Richardson, and D. A. Frank Identification of a Genetic Signature of Activated Signal Transducer and Activator of Transcription 3 in Human Tumors Cancer Res., June 15, 2005; 65(12): 5054 - 5062. [Abstract] [Full Text] [PDF]

				D. Zips, W. Eicheler, P. Geyer, F. Hessel, A. Dorfler, H. D. Thames, M. Haberey, and M. Baumann Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition Cancer Res., June 15, 2005; 65(12): 5374 - 5379. [Abstract] [Full Text] [PDF]

				K. J. Till, D. G. Spiller, R. J. Harris, H. Chen, M. Zuzel, and J. C. Cawley CLL, but not normal, B cells are dependent on autocrine VEGF and {alpha}4{beta}1 integrin for chemokine-induced motility on and through endothelium Blood, June 15, 2005; 105(12): 4813 - 4819. [Abstract] [Full Text] [PDF]

				S. Lee, S. M. Jilani, G. V. Nikolova, D. Carpizo, and M. L. Iruela-Arispe Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors J. Cell Biol., May 23, 2005; 169(4): 681 - 691. [Abstract] [Full Text] [PDF]

				X. Jimenez, D. Lu, L. Brennan, K. Persaud, M. Liu, H. Miao, L. Witte, and Z. Zhu A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3 Mol. Cancer Ther., March 1, 2005; 4(3): 427 - 434. [Abstract] [Full Text] [PDF]

				B. I. Rini VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma Oncologist, March 1, 2005; 10(3): 191 - 197. [Abstract] [Full Text] [PDF]

				B. I. Rini and E. J. Small Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043. [Abstract] [Full Text] [PDF]

				D. J. Hicklin and L. M. Ellis Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027. [Abstract] [Full Text] [PDF]

				D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668 Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689. [Abstract] [Full Text] [PDF]

				R. K. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science, January 7, 2005; 307(5706): 58 - 62. [Abstract] [Full Text] [PDF]

				A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]

				H. Kobayashi, K. Reijnders, S. English, A. T. Yordanov, D. E. Milenic, A. L. Sowers, D. Citrin, M. C. Krishna, T. A. Waldmann, J. B. Mitchell, et al. Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation Clin. Cancer Res., November 15, 2004; 10(22): 7712 - 7720. [Abstract] [Full Text] [PDF]

				G. Bocci, S. Man, S. K. Green, G. Francia, J. M. L. Ebos, J. M. du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Res., September 15, 2004; 64(18): 6616 - 6625. [Abstract] [Full Text] [PDF]

				W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J. Clin. Pathol., September 1, 2004; 57(9): 965 - 969. [Abstract] [Full Text] [PDF]

				J. M. Davison, V. Homuth, A. Jeyabalan, K. P. Conrad, S. A. Karumanchi, S. Quaggin, R. Dechend, and F. C. Luft New Aspects in the Pathophysiology of Preeclampsia J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2440 - 2448. [Abstract] [Full Text] [PDF]

				N. Ferrara Vascular Endothelial Growth Factor: Basic Science and Clinical Progress Endocr. Rev., August 1, 2004; 25(4): 581 - 611. [Abstract] [Full Text] [PDF]

				S. S. Yoon, N. H. Segal, A. B. Olshen, M. F. Brennan, and S. Singer Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma Ann. Onc., August 1, 2004; 15(8): 1261 - 1266. [Abstract] [Full Text] [PDF]

				D. W. Davis, K. Inoue, C. P. N. Dinney, D. J. Hicklin, J. L. Abbruzzese, and D. J. McConkey Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts Cancer Res., July 1, 2004; 64(13): 4601 - 4610. [Abstract] [Full Text] [PDF]

				D. Chakroborty, C. Sarkar, R. B. Mitra, S. Banerjee, P. S. Dasgupta, and S. Basu Depleted Dopamine in Gastric Cancer Tissues: Dopamine Treatment Retards Growth of Gastric Cancer by Inhibiting Angiogenesis Clin. Cancer Res., July 1, 2004; 10(13): 4349 - 4356. [Abstract] [Full Text] [PDF]

				H. Rossiter, C. Barresi, J. Pammer, M. Rendl, J. Haigh, E. F. Wagner, and E. Tschachler Loss of Vascular Endothelial Growth Factor A Activity in Murine Epidermal Keratinocytes Delays Wound Healing and Inhibits Tumor Formation Cancer Res., May 15, 2004; 64(10): 3508 - 3516. [Abstract] [Full Text] [PDF]

				J. Sun, M. A. Blaskovich, R. K. Jain, F. Delarue, D. Paris, S. Brem, M. Wotoczek-Obadia, Q. Lin, D. Coppola, K. Choi, et al. Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor Cancer Res., May 15, 2004; 64(10): 3586 - 3592. [Abstract] [Full Text] [PDF]

				A M Jubb, T Q Pham, A M Hanby, G D Frantz, F V Peale, T D Wu, H W Koeppen, and K J Hillan Expression of vascular endothelial growth factor, hypoxia inducible factor 1{alpha}, and carbonic anhydrase IX in human tumours J. Clin. Pathol., May 1, 2004; 57(5): 504 - 512. [Abstract] [Full Text] [PDF]

				B. I. Rini, S. Halabi, J. Taylor, E. J. Small, and R. L. Schilsky Cancer and Leukemia Group B 90206: A Randomized Phase III Trial of Interferon-{alpha} or Interferon-{alpha} Plus Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Metastatic Renal Cell Carcinoma Clin. Cancer Res., April 15, 2004; 10(8): 2584 - 2586. [Abstract] [Full Text] [PDF]

				G. Hopfl, O. Ogunshola, and M. Gassmann HIFs and tumors--causes and consequences Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2004; 286(4): R608 - R623. [Abstract] [Full Text] [PDF]

				T.-G. Cui, R. R. Foster, M. Saleem, P. W. Mathieson, D. A. Gillatt, D. O. Bates, and S. J. Harper Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein Am J Physiol Renal Physiol, April 1, 2004; 286(4): F767 - F773. [Abstract] [Full Text] [PDF]

				S. Kanda, Y. Miyata, and H. Kanetake Fibroblast Growth Factor-2-mediated Capillary Morphogenesis of Endothelial Cells Requires Signals via Flt-1/Vascular Endothelial Growth Factor Receptor-1: POSSIBLE INVOLVEMENT OF c-Akt J. Biol. Chem., February 6, 2004; 279(6): 4007 - 4016. [Abstract] [Full Text] [PDF]

				N. J. Boudreau and J. A. Varner The Homeobox Transcription Factor Hox D3 Promotes Integrin {alpha}5{beta}1 Expression and Function during Angiogenesis J. Biol. Chem., February 6, 2004; 279(6): 4862 - 4868. [Abstract] [Full Text] [PDF]